企業プロフィール
BioAtla, Inc. 株価・ニュース・カタリスト
- ティッカー:
- BCAB
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
3.18 USD (0.00%)
終値
最終更新: 2026年8月21日
5.85M USD
時価総額
株価変動の要因
As of Aug 21, 2026, BCAB was little changed and closed at $3.18. No new same-company headline was identified in the current news window.
企業概要
Conditionally Active Biologics
BioAtla develops antibodies engineered to bind preferentially under conditions found in the tumor microenvironment. The CAB platform uses factors such as acidic pH to reduce target binding in normal tissue and potentially limit on-target, off-tumor toxicity.
BA3182
BA3182 is a conditionally active EpCAM and CD3 bispecific T-cell engager in Phase 1 development for advanced adenocarcinomas. Both binding arms are designed to activate preferentially within tumors.
Antibody-Drug Conjugates
The clinical ADC portfolio includes ozuriftamab vedotin against ROR2 and mecbotamab vedotin against AXL. Programs have been studied in oropharyngeal cancer, sarcoma and KRAS-mutant lung cancer.
Broader CAB Pipeline
Evalstotug is a conditionally active CTLA-4 antibody, while preclinical assets target Nectin-4, B7H4, B7H3, EGFR and Trop2. BioAtla is evaluating strategic transactions and may alter the pace or scope of these programs while preserving capital.
今後のカタリスト
- BioAtla’s catalysts are conditional-activation antibodies and any oncology update that shows the platform can still differentiate. The company remains data-sensitive because the platform story is not yet fully proven.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。